A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.
A CROI 2019 study suggests the dynamics of HIV proliferation in the viral reservoir might explain why viral load sometimes fails to become undetectable, especially when adherence is good.
Gina Brown, M.D., shares her reflections on some of the many research findings about HIV prevention, care, and treatment for women and girls presented at CROI 2018.
Two video interviews with federal HIV leaders who share their perspectives about the science coming out of the conference and its implications for HIV prevention, care, and treatment.
No HIV Evolution in Plasma or Lymph Nodes on Suppressive ART and No Impact From Further Intensification
Two studies presented at CROI 2018 support the idea that ART reaches everywhere in the body that it needs to, and that residual ongoing HIV replication comes from HIV infected cells that were archived before ART was started.
A Facebook Live interview with NIAID Division of AIDS director Carl Dieffenbach, Ph.D., about some of the key research findings presented during the first full day of sessions at CROI 2018.
A review of the effect of rifampin on tenofovir alafenamide (TAF) plasma/intracellular pharmacokinetics presented at CROI 2018.
It's strange to think about the Conference on Retroviruses and Opportunistic Infections (CROI) being the hottest ticket in town. But for the research community, CROI is in fact one of the more significant annual conferences on the latest HIV research...
"At CROI, the 'executive director hat' comes off, and I'm purely a community advocate again," Rob Newells writes. "This year, that was even more true than in previous years."
One study in Amsterdam deployed a strategy to identify acute HIV in men who have sex with men (MSM) and then link newly diagnosed individuals to care.